3 / 9
Page 11
Notes:
Biol Med Case Rep 2017 | Volume 1 Issue 2
allied
academies
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
N
anodrugs, like nanoparticles, are known to be taken
up by the cells of the reticuloendothelial system
(RES), resulting in a great majority of these particles/drugs
not being delivered to the target sites, namely tumors.
Consequently, these drugs can cause serious toxic side effects
in liver, spleen, and kidney. Various attempts (including the
“stealth” strategy) have been made to alleviate these side
effects, but none has been fully successful. These toxic
effects have presented a serious challenge to making use of
these nanodrugs for treatment of diseases. Our approach
is to temporarily blunt the RES by a prior administration of
an FDA approved nutrition supplement, Intralipid®, before
dosing rats with a nanodrug. We have applied four anti-
cancer nanodrugs, namely an in-development platinum
(Pt)-containing anti-cancer nanodrug, and three FDA
approved anti-cancer nanodrugs, Abraxane®, Onivyde®, and
Marqibo®, to test our methodology. In this talk, we will give
a summary of recent results. We have observed different
toxicities for these four nanodrugs and have found that
Intralipid® can reduce their toxic side effects in the RES and
kidney of rats to different levels. Intralipid® methodology
could be a valuable complement to the current techniques,
e.g., stealth strategies, to reduce RES uptake and toxicity.
Our approach is a general one applicable to any approved
and in-development nanodrugs without any modification of
the nanoparticles, thus facilitating their translation to clinical
settings.
Speaker Biography
Dr. Ho received his BA degree in Chemistry from Williams College and his PhD degree
in Physical Chemistry from Yale University. From 1961-64, he took his postdoctoral
training in the Departments of Chemistry and of Biology at Massachusetts Institute
of Technology. He is Alumni Professor of Biological Sciences at Carnegie Mellon
University. His research goal is to understand the relationships between structure and
function in biological systems by correlating information obtained from biochemical,
biophysical, and molecular biological techniques. He has two major research projects,
one on the structure-function relationship in hemoglobin and the other on imaging
immune responses
in vivo
by MRI using animal models. He has co-authored over
300 scientific papers. He has received a number of awards and honors including
the election to Academician of Academia Sinica, Fellow of the International Society
of Magnetic Society (ISMAR), the International Society of Magnetic Resonance in
Medicine (ISMRM), and the American Association for the Advancement of Science
(AAAS). He is a recipient of a John Simon Guggenheim Fellowship, a MERIT Award
of the National Heart, Lung, and Blood Institute, and a Gold Medal of ISMRM for his
contribution to the development of
in-vivo
cell tracking methodology by MRI.
e:
chienho@andrew.cmu.eduChien Ho
Carnegie Mellon University, USA
A new approach to deliver anti-cancer nanodrugs and to reduce toxicity by
temporarily blunting the reticuloendothelial system